In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

Flavia Pichiorri, Dario Palmieri, Luciana De Luca, Jessica Consiglio, Jia You, Alberto Rocci, Tiffany Talabere, Claudia Piovan, Alessandro Lagana, Luciano Cascione, Jingwen Guan, Pierluigi Gasparini, Veronica Balatti, Gerard Nuovo, Vincenzo Coppola, Craig C. Hofmeister, Guido Marcucci, John C. Byrd, Stefano Volinia, Charles L. ShapiroMichael A. Freitas, Carlo M. Croce

Research output: Contribution to journalArticlepeer-review


Numerous studies have described the altered expression and the causal role of microRNAs (miRNAs) in human cancer. However, to date, efforts to modulate miRNA levels for therapeutic purposes have been challenging to implement. Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance. We also show that NCL is commonly overexpressed in human breast tumors and that its expression correlates with that of NCL-dependent miRNAs. Finally, inhibition of NCL using guanosine-rich aptamers reduces the levels of NCL-dependent miRNAs and their target genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo. These findings illuminate a path to novel therapeutic approaches based on NCLtargeting aptamers for the modulation of miRNA expression in the treatment of breast cancer.

Original languageEnglish
Pages (from-to)951-968
Number of pages18
JournalJournal of Experimental Medicine
Issue number5
Publication statusPublished - May 2013

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)


Dive into the research topics of 'In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation'. Together they form a unique fingerprint.

Cite this